Abstract
Improved knowledge and understanding of key aspects of cancer has led to the development of novel cancer therapeutics acting through complex pathways and mode of actions. The success of these novel cancer therapeutics is often difficult to predict using standard response criteria based on anatomic changes. Monitoring response to cancer therapy at molecular level using Positron Emission Tomography (PET) has gained popularity in recent years. PET allows longitudinal assessment of specific biological processes rather than just changes in anatomic changes in tumor size. In this review, we provide an overview on application for PET imaging to monitor cancer therapy with emphases on PET of tumor metabolism, cell proliferation, angiogenesis, hypoxia and receptor dynamics.
Keywords: Biomarker, Cancer, Molecular imaging, Monitoring response to therapy, Positron Emission Tomography.
Current Pharmaceutical Biotechnology
Title:PET Imaging to Monitor Cancer Therapy
Volume: 14 Issue: 7
Author(s): Gaurav Malviya and Tapan K. Nayak
Affiliation:
Keywords: Biomarker, Cancer, Molecular imaging, Monitoring response to therapy, Positron Emission Tomography.
Abstract: Improved knowledge and understanding of key aspects of cancer has led to the development of novel cancer therapeutics acting through complex pathways and mode of actions. The success of these novel cancer therapeutics is often difficult to predict using standard response criteria based on anatomic changes. Monitoring response to cancer therapy at molecular level using Positron Emission Tomography (PET) has gained popularity in recent years. PET allows longitudinal assessment of specific biological processes rather than just changes in anatomic changes in tumor size. In this review, we provide an overview on application for PET imaging to monitor cancer therapy with emphases on PET of tumor metabolism, cell proliferation, angiogenesis, hypoxia and receptor dynamics.
Export Options
About this article
Cite this article as:
Malviya Gaurav and Nayak K. Tapan, PET Imaging to Monitor Cancer Therapy, Current Pharmaceutical Biotechnology 2013; 14(7) . https://dx.doi.org/10.2174/1389201014666131226104750
DOI https://dx.doi.org/10.2174/1389201014666131226104750 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (SERMs) in Biological Fluids
Current Chromatography Malignant Hypercalcemia
Current Medicinal Chemistry Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data
Current Gene Therapy Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design The Delicate Balance between the Good and the Bad IL-1 Proinflammatory Effects in Endometriosis
Current Medicinal Chemistry Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science